Background: Outcome of intermediate risk rectal cancer may be improved by the addition of oxaliplatin during 5-fluoruracil concomitant neoadjuvant chemoradiotherapy. The purpose of this study is to analyze the main clinical results of the ACCORD12 trial (NCT00227747) in rectal cancer after 5 years of follow-up.
Patients and methods: Inclusion criteria were as follows: rectal adenocarcinoma accessible to digital examination staged T3-T4 Nx M0 (or T2 Nx distal anterior rectum). Two neoadjuvant chemoradiotherapy regimens were randomized: CAP45 (RT 45 Gy þ capecitabine) and CAPOX50 (RT 50 Gy þ capecitabine and oxaliplatin). Main end point was sterilization of the operative specimen. Acute and late toxicities were prospectively analyzed with dedicated questionnaires.
Results: Between November 2005 and July 2008, 598 patients were included in the trial. After a median follow-up of 60.2 months, there was no difference between treatment arms in multivariate analysis either for disease-free survival or overall survival (OS) [P ¼ 0.9, hazard ratio (HR)¼1.02; 95% confidence interval (CI), 0.76-1.36 and P ¼ 0.3, HR ¼ 0.87; 95% CI, 0.66-1.15, respectively]. There was also no difference of local control in univariate analysis (P ¼ 0.7, HR ¼ 0.92; 95% CI, 0.51-1.66). Late toxicities were acceptable with 1.6% G3 anal incontinence, and <1% G3 diarrhea, G3 rectal bleeding, G3 stenosis, G3-4 pain, G3 urinary incontinence, G3 urinary retention and G3 skeletal toxicity. There was a slight increase of erectile dysfunction over time with a 63% rate of erectile dysfunction at 5 years. There was no significant statistical difference for these toxicities between treatment arms.
Introduction
The standard treatment of T3-T4 and/or N-positive M0 rectal cancers is surgery with total mesorectal excision [1] . The addition of radiotherapy reduces the local relapse rate, as demonstrated by several randomized trials [2, 3] . Further increase of local control was permitted by positioning radiotherapy in the neoadjuvant setting and by addition of fluorouracil chemotherapy [4, 5] . None of these trials reported a survival benefit and new strategies are needed to improve disease-free survival (DFS) and overall survival (OS) in nonmetastatic rectal cancer. The addition of oxaliplatin to fluoropyrimidine-based adjuvant chemotherapy of colon cancer demonstrated a DFS and OS benefit. Consequently, this combination was tested in several trials, concomitantly with neodjuvant radiotherapy. Apart from the German CAO/ARO/ AIO-04 study, there was no improvement of complete pathologic response, local control, DFS or OS [6] [7] [8] [9] . In the present study, we report long-term outcomes of the Actions concertées dans les Cancers Colorectaux et Digestifs (ACCORD) 12 trial, which randomized the use of concomitant oxaliplatin during neoadjuvant chemoradiotherapy in intermediate risk rectal cancer [6] .
Methods

Patients
Inclusion criteria were as follows: histologically proven adenocarcinoma, accessible to digital rectal examination, staged T2 Nx distal anterior rectum or T3-T4 Nx M0 (by endorectal ultrasound and/or magnetic resonance imaging).
Randomization and procedures
CAP45 was the control arm: patients received 45 Gy in 25 sessions, one session daily, over 5 weeks (1.8 Gy per fraction) with concurrent capecitabine 800 mg/m 2 twice daily delivered on each radiation day). CAPOX50 regimen was the experimental arm: patients received 50 Gy in 25 sessions, one session daily, over 5 weeks (2 Gy per fraction) and addition of oxaliplatin 50 mg/m 2 administered once weekly for 5 weeks) and concurrent capecitabine 800 mg/m 2 twice daily delivered on each radiation day. Patients were randomized between these 2 arms (ratio 1:1). Stratification was done by sex, T-stage (cT2, cT3, cT4), center and distance from anal verge ( 6 versus > 6 cm) (supplementary Data S1, available at Annals of Oncology online).
At least 8 MV photons were used for the radiotherapy with a three-or four-field technique including the mesorectal and medial rectal nodes while excluding common iliac and external iliac lymph nodes (supplementary Data S3, available at Annals of Oncology online).
Surgery with total mesorectal excision was planned 6 weeks after the end of preoperative chemoradiotherapy (supplementary Data S3, available at Annals of Oncology online). Modified Dworak score was used for pathological examination (supplementary Data S3, available at Annals of Oncology online) [10] . Follow-up was carried out 3 months after surgery and then every 6 months for 5 years. The analysis of toxicities was carried out according to the National Cancer Institute Common Toxicity Criteria, version 3.0.
Bowel function was evaluated according to the anal sphincterconserving treatment questionnaire (ASCT, supplementary Data S2, available at Annals of Oncology online). This questionnaire was completed by the patient before treatment and every 6 months thereafter.
Erectile dysfunction (ED): the patient was asked to state if he experienced ED or not, before treatment and every 6 months. For patients reporting ED, a satisfaction degree was indicated. Satisfaction degree ranges from 1 (ED) to 7 (normal erectile function).
Social life disruption: analyzed with one question: 'During the past week, was your social life disrupted (going out, visiting friends, travel, sport . . .) 1) a lot, 2) moderately, 3) slightly, or 4) not at all?'.
Statistical analysis
According to the intention-to-treat principle, the present analysis included all patients who underwent randomization. The primary end point was pathological complete response (ypCR). Secondary end points were OS, DFS, circumferential rectal margin, sphincter preservation and local control. Clinical secondary end points were defined in a previous publication [6] .
Further details of statistical analysis are reported in supplementary Data S3, available at Annals of Oncology online. Evolution of all toxicity scores during follow-up visits was analyzed using a Linear Mixed Model.
Results
Patient characteristics
Five hundred ninety-eight patients were included between November 2005 and July 2008 through 56 institutions ( Figure 1D ).
Patients included in the intention-to-treat analysis are described in Table 1 . Patient characteristics were well-balanced between both arms except for age, which was significantly lower in the CAPOX50 arm (61 versus 63 years, P ¼ 0.01).
Events, DFS and OS
Intention-to-treat analysis of crude events is detailed in supplementary Table S1 , available at Annals of Oncology online. After a median follow-up of 60.2 months, there were 44 local recurrences, 159 distant metastases, 21 second cancers and 130 deaths. The 5-year rate of local recurrence was not statistically different between arms (8.8% and 7.8% in CAP50 and CAPOX50, respectively, P ¼ 0.7, hazard ratio [HR] ¼ 0.92; 95% confidence interval [CI], 0.51-1.66, Figure 1C ). The 5-year rate of distant metastasisfree survival was not significantly different between arms: 70.8% and 72.9% in CAP45 and CAPOX50, respectively (P ¼ 0.5, HR ¼ 0.90; 95% CI, 0.66-1.23). The 5-year DFS rate was not different between arms: 63.1% in the CAP45 arm versus 66.1% in the CAPOX50 arm (P ¼ 0.3, HR ¼ 0.86; 95% CI, 0.66-1.15) ( Figure 1A ).
The 5-year OS rates were 73% and 82% in the CAP45 and the CAPOX50 arms, respectively. Although the difference in survivor functions did not reach statistical significance, there was a trend toward a treatment effect favoring CAPOX50 in terms of OS in univariate analysis (HR ¼ 0.71; 95% CI, 0.50-1.01, P ¼ 0.056) ( Figure 1B ). Median OS was not reached in the CAPOX50 arm and was 84 months in the CAP45 arm.
Prognostic factors for OS and DFS are described in Table 2 and  Table 3 , respectively (detailed analysis is provided in supplementary Table S5 , available at Annals of Oncology online).
Independent prognostic factors for worse OS and DFS were as follows: older age (!75 years), elevated ypN (ypN2) and worse Dworak score (response other than 3 or 4). Regarding DFS, no subgroup benefited from the addition of oxaliplatin (Forest plot analysis, supplementary Figure S2 , available at Annals of Oncology online); for OS, male gender, ypN0, partial or complete pathological responses and conservative surgery subgroups benefited from the addition of oxaliplatin (supplementary Figure S2 , available at Annals of Oncology online).
Compliance, early toxicities and late toxicities
Full-dose radiotherapy was given in 87% of patients in the CAPOX50 arm versus 100% in the CAP45 arm. Dose changes in the chemotherapy regimen were made in 59% of patients in the CAPOX50 arm versus 50% in the CAP45 arm. As reported previously [11] , acute toxicity was greater in the CAPOX50 arm with an overall 25.4% rate of grade 3 to 4 toxicity in the CAPOX50 arm than in the CAP45 arm with 10.9% (P < 0.001), mainly due to an increase in diarrhea (12.6% versus 3.2%, P < 0.001). Adjuvant chemotherapy was given equally in both arms.
The maximum toxicity grade was reported every year over 5 years. There was no difference in terms of late radiation toxicities (Table 4 and supplementary Table S4 , available at Annals of Oncology online). Detailed description of these toxicities is available in supplementary Table S2 , available at Annals of Oncology online: we observed 2% G3 anal incontinence, less than 1% G3 diarrhea, G3 rectal bleeding, G3 stenosis, G3-4 pain, G3 urinary incontinence G3 urinary retention and G3 skeletal toxicity. ED: 63% of patients at 5 years declared abnormal function with no significant difference between groups (supplementary Table S2 , available at Annals of Oncology online). At 18 and 36 months after inclusion, patients with low rectal tumors had an increased risk of ED with respect to patients with middle tumors (18 months: 89.1% versus 63.6%, P ¼ 0.01; 36 months: 75% versus 47.4%, P ¼ 0.03). There was no significant difference after 60 months (80% versus 60%, P ¼ 0.2). Regarding neurological toxicities, there were 12 and 10 patients, respectively, with peripheral neuropathy in CAP45 and CAP50 (14 G1, 5 G2 and 3 G3).
Supplementary Table S3 , available at Annals of Oncology online describes evolution of the ASCT score for each question. Besides modifying lifestyle, which worsened with time, most symptoms improved 3 months after surgery (6 months after inclusion). Consequently, disruption of social life decreased and global satisfaction improved 3 months after surgery (supplementary Figure S1 , available at Annals of Oncology online).
Compared with CAPOX50, patients in the CAP45 arm took less medication against diarrhea (Question 1, P ¼ 0.008), needed to open their bowels less frequently after having already done so (Question 5, P ¼ 0.006), presented fewer fecal leakages (Question 8, P ¼ 0.01), needed less protection against loose stools (Question 13, P ¼ 0.02) and felt the need less often to open their bowels with no success (Question 14, P ¼ 0.01). Differences of response to these questions between treatment arms were small. There was no statistical difference for other questions in the ASCT score (P > 0.05). Analysis of ASCT questions is available in supplementary Table S3 , available at Annals of Oncology online.
Discussion
Outcomes of patients included in the ACCORD 12 phase III trial are reported in this study after a median follow-up of 5 years. The addition of preoperative oxaliplatin to the 5-FU regimen and the increase of total radiation dose from 45 to 50 Gy failed to increase either the 5-year DFS rate or the 5-year OS rate. However, this study was not powered to detect a statistical difference for these outcomes but was powered to detect a difference in ypCR from 11% to 20% (a ¼ 0.05 two-tailed, b ¼ 0.15). As reported previously, the primary end point was not reached with an increase of ypCR from 13.9% to 19.2% (P ¼ 0.09) [11] . Regarding results of the ACCORD12, NSABP-R04 [8] and STAR-01 [7] trials, we may speculate that the increase in tumor response rate was due to the increase in radiation dose rather than to the addition of oxaliplatin. Indeed, the 5 Gy increase led to a significant increase in biological effective dose (BED) of 13% (if 45 Gy, 1.8 Gy per session, BED ¼ 53.1 Gy; if 50 Gy, 2 Gy per session, BED ¼ 60 Gy, a/b ¼ 10 for colorectal cancer). Interestingly, the effects of radiotherapy dose on pathological complete response (pCR) was identified as an independent predictor of pCR in a retrospective study analyzing the SEER data base (3298 patients) [12] .
The 5-year local control rate was about 8% in both arms, which was somewhat not only higher than the 4%-7% rate in the German trial [9] but also lower than the American trial (11%) [8] . However, it is difficult to compare these results since the radiotherapy and chemotherapy regimens differed slightly between these trials.
In the ACCORD12 trial (NCT00227747), adjuvant chemotherapy had no impact on either DFS or OS in multivariate analysis. The trial was not designed to answer this question although some trials specifically address this issue (NCT02167321 and NCT00349076).
Regarding toxicities, there were no differences between the arms for ED, gastrointestinal, urologic or peripheral neuropathy or skeletal toxicities. A dedicated exhaustive questionnaire to collect these toxicities was not carried out. This constitutes a limitation, particularly regarding low-grade toxicities. Late anal function was prospectively evaluated by the ASCT score and revealed a slightly worse function in CAPOX50 with increased fecal leakages, a need for protection against loose stools and a need for medication against diarrhea. This study provides detailed analysis of grade 1-5 late urinary, digestive, sexual and bone toxicities, which were recorded prospectively. The completion rate of ASCT and quality of life questionnaires was around 78.8% at inclusion and then around 40% each year after surgery. This may have biased results since unfit patients may have refused to complete the questionnaire. The toxicity rates observed in the ACCORD12 trial are somewhat lower than in other studies, probably because the irradiated volume in the ACCORD12 trial had to exclude common and external iliac lymph nodes. Birgisson et al. [13] reviewed toxicities after radiation therapy for rectal cancer, the German Rectal Cancer Study Group reported a 15% rate of late G3-G4 toxicities [14] , and the Polish trial found no significant differences between the short (5 Â 5 Gy) and the long RT courses (25 Â 1.8 Gy þ 5-FU) [15] with similar late toxicities. The TransTasman Radiation Oncology Group Trial 01.04 reported similar toxicities at 3 years with a low rate of grade 3-4 toxicities (1% skin, 5%-8% small/large intestine, 2%-3% bladder) [16] . The same trial also described results regarding health-related quality of life at 1 year [17] : patients reported low scores on sexual functioning and sexual enjoyment and an initial decrease of health-related quality of life, which later increased, as in the ACCORD12 trial. Most ASCT questions showed the same tendency with worse outcome after surgery during the first 6 months which then returned approximately to baseline. The analyses of quality of life and ED during the ACCORD12 trial did not use dedicated/generic questionnaires such as the EORTC QLQ-C30, the EORTC QLQ-CR29 or the IIEF questionnaires. This is a limitation since small changes may have been missed for these end points. Also, sexual function in women was not analyzed during the ACCORD-12 trial. Independent prognostic factors for worse OS and DFS were as follows: older age (!75 years), elevated ypN (ypN2) and worse Dworak score (response other than major or complete response). Treatment arm did not correlate with either DFS or OS in univariate or multivariate analysis. The trend seen for worse OS with CAP45 in univariate analysis (P ¼ 0.055, HR ¼ 0.78; 95% CI, 0.53-1.15]) was probably due to a more advanced age in the CAP45 group at baseline (63 versus 61 years old, P ¼ 0.01). Finally, the addition of oxaliplatin did not increase survival advantage in the ACCORD 12 trial. Also, most other trials showed neither a DFS nor an OS advantage by addition of oxaliplatin concurrently with irradiation [7, 8] . This was also demonstrated previously in tumor xenograft models (HT29 cells) where the addition of oxaliplatin to 5-FU and ionizing radiation did not reduce tumor growth [18] . In the German CAO/ARO/AIO-94 trial, Rödel et al. [9] tested the addition of oxaliplatin to infusional fluoruracil in the same setting and reported a 5-year DFS advantage in the experimental arm (75.9% versus 71.2%, P ¼ 0.03). 5-FU administration differed between the control and experimental arms, which may have influenced the survival results.
In order to increase survival in these patients, other trials are ongoing with new neoadjuvant chemotherapy strategies (rectal cancer and per-operative induction therapy followed by dedicated operation (RAPIDO) [NCT01558921], partenariat de recherche en oncologie digestive (PRODIGE) 23 [NCT01804790] and chemotherapy alone or chemotherapy plus radiation therapy in treating patients with locally advanced rectal cancer undergoing surgery (PROSPECT) [NCT01515787] trials). Other clinical trials are testing higher doses of radiotherapy in order to increase the clinical complete response rate (<20%) with a view to limiting the extent of surgery (organ preservation in early rectal adenocarcinoma (OPERA) trial: NCT02505750 and the British STAR TREC (saving the rectum by active surveillance or TransAnal surgery after (chemo) radiotherapy versus total mesorectal excision for early rectal cancer) trial).
In conclusion, oral capecitabine plus the 50 Gy regimen are now considered the standard of care in France and in many new clinical trials because (i) 50 Gy may enhance tumor response without increasing the late toxicities rate and (ii) oral capecitabine was non inferior to intravenous 5-FU as reported in the NSABP R-04 trial [8] . Based on the negative results of the ACCORD12, STAR-01, NSABP-R04 and PETACC-6 trials [7, 8, 19] , the addition of oxaliplatin at a radiosensitizing dose to fluoropyrimidine-based chemoradiotherapy cannot be recommended in routine practice and further investigation of this strategy is not warranted.
